Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.

Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS.

J Immunother Cancer. 2019 Aug 10;7(1):214. doi: 10.1186/s40425-019-0682-1.

2.

Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.

Hafsi H, Dillon MT, Barker HE, Kyula JN, Schick U, Paget JT, Smith HG, Pedersen M, McLaughlin M, Harrington KJ.

Front Oncol. 2018 Jul 13;8:245. doi: 10.3389/fonc.2018.00245. eCollection 2018.

3.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaar2041. doi: 10.1126/scitranslmed.aar2041.

4.

HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.

McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, Mansfield DC, Patel R, Kyula JN, Bhide SA, Newbold KL, Nutting CM, Harrington KJ.

BMC Cancer. 2017 Jan 31;17(1):86. doi: 10.1186/s12885-017-3084-0.

5.

Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.

McEntee G, Kyula JN, Mansfield D, Smith H, Wilkinson M, Gregory C, Roulstone V, Coffey M, Harrington KJ.

Oncotarget. 2016 Jul 26;7(30):48517-48532. doi: 10.18632/oncotarget.10365.

6.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.

7.

Adenovirally delivered enzyme prodrug therapy with herpes simplex virus-thymidine kinase in composite tissue free flaps shows therapeutic efficacy in rat models of glioma.

Seth R, Khan AA, Pencavel TD, Wilkinson MJ, Kyula JN, Simpson G, Pandha H, Melcher A, Vile R, Harris PA, Harrington KJ.

Plast Reconstr Surg. 2015 Feb;135(2):475-87. doi: 10.1097/PRS.0000000000000878.

8.

Radiation lays down covering fire for viral shock troops.

Kyula JN, Khan AA, Wilkinson MJ, Mansfield D, Harrington KJ.

Oncotarget. 2013 Sep;4(9):1329-30. No abstract available.

9.

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ.

Oncogene. 2014 Mar 27;33(13):1700-12. doi: 10.1038/onc.2013.112. Epub 2013 Apr 29.

10.

Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.

Kyula JN, Roulstone V, Karapanagiotou EM, Melcher AA, Harrington KJ.

Expert Opin Biol Ther. 2012 Dec;12(12):1669-78. doi: 10.1517/14712598.2012.745507. Review. Erratum in: Expert Opin Biol Ther. 2013 Jan;13(1):147.

PMID:
23140488
11.

Targeted radiosensitization by the Chk1 inhibitor SAR-020106.

Borst GR, McLaughlin M, Kyula JN, Neijenhuis S, Khan A, Good J, Zaidi S, Powell NG, Meier P, Collins I, Garrett MD, Verheij M, Harrington KJ.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1110-8. doi: 10.1016/j.ijrobp.2012.08.006. Epub 2012 Sep 14.

PMID:
22981708
12.

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

Oral Oncol. 2013 Feb;49(2):108-18. doi: 10.1016/j.oraloncology.2012.07.019. Epub 2012 Aug 25.

PMID:
22925693
13.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16.

14.

Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.

Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG.

Cancer Res. 2011 Feb 1;71(3):1071-80. doi: 10.1158/0008-5472.CAN-10-0714. Epub 2010 Dec 10.

15.

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.

Kyula JN, Van Schaeybroeck S, Doherty J, Fenning CS, Longley DB, Johnston PG.

Clin Cancer Res. 2010 Jul 1;16(13):3378-89. doi: 10.1158/1078-0432.CCR-10-0014. Epub 2010 Jun 22.

Supplemental Content

Loading ...
Support Center